Novo Nordisk Bets DKK 150 Billion on Pipeline Diversification, Promises 10x Oral Capacity and Head-to-Head Data Showing CagriSema Beats Tirzepatide at Matched Doses
Capital Markets Day, London, September 21, 2026
Novo Nordisk used its first Capital Markets Day in two years to lay out the most detailed roadmap yet for life after semaglutide's patent cliff, promising a materially larger and more diversified company by 2035 even as it absorbed a brutal 13,000-person headcount reduction over the past year. CEO Maziar Doustdar set the tone early, telling the room "we do not belittle LOE or the challenges that comes with it," before pivoting to the company's central pitch: a risk-adjusted pipeline value of more than DKK 150 billion by 2030, at least five multi-blockbuster launches, and a 10-fold expansion of oral manufacturing capacity to serve 15 million patients on the Wegovy pill, up from 1.5 million today.
CagriSema Data Reframes the Efficacy Debate
The most concrete new data point of the day came from REIMAGINE 5, a 1,000-patient head-to-head study comparing CagriSema at its lowest dose (1 milligram) against tirzepatide at its most commonly prescribed real-world dose (5 milligrams) — not the headline maximum doses typically compared in investor models. CagriSema delivered 12.5% weight loss versus 9% for tirzepatide, with identical glycemic control. R&D chief Martin Lange called this "clinically relevant" and "reflective of what happens for the majority of patients in the real world," directly countering the narrative that CagriSema's REDEFINE 1 headline of 23% weight loss trailed the field. Management also disclosed a small Phase II study showing CagriSema produced a 2.4-point reduction in neuropathic pain in diabetes patients versus roughly 1 point for gabapentinoids — data one unnamed key opinion leader described, in Lange's telling, as "a potential game changer in the space of diabetes because no innovation have come into this space." CagriSema also showed doubled physical function scores and preserved muscle strength despite the weight loss, addressing investor concerns about lean mass loss. Regulatory approval is expected in the fourth quarter of this year, with REDEFINE 11 data — closely watched for whether higher doses can push weight loss beyond 23% — due in the first quarter of 2027, timed to coincide with the U.S. launch.
A Formal Pivot Into Four New Growth Engines
Beyond the core diabetes and obesity franchise, Novo formally established three new segments: blood and endocrine disorders, liver disease, and cardiovascular disease, alongside an exploratory "Consumer Rx" category that Doustdar was careful to distinguish from conventional over-the-counter strategy. "This is where Novo has become second to none in expertise over the last 2 to 3 years in our ability to take a prescription medication and directly provide that to the consumers," he said. Blood and endocrine — built on decades of hemophilia and growth hormone expertise — is targeted to grow more than 50% by 2030, powered by three near-term blockbuster launches: Frehemgo in hemophilia A (already carrying a CHMP positive opinion and a first global approval in Saudi Arabia), etavopivat in sickle cell disease, and zaltenibart in complement-mediated hemato-renal disease. Liver disease centers on efruxifermin, acquired via the Akero deal, which showed both steatohepatitis and fibrosis reduction in F4 MASH patients — the segment with no approved treatment today and where, as Habib Bennaceur noted, liver transplants can cost up to $1 million. Cardiovascular strategy pivots away from the failed ZEUS trial's IL-6 approach toward NLRP3 inhibition and an oral PCSK9 combination with next-generation GLP-1s, though Lange was candid that "it's still early days."
R&D Speed and AI Claims Get Concrete Numbers
Novo disclosed that first-human-dose starts — its proxy for research productivity — will jump from just 3 in 2025 to at least 10 (potentially 15-16) this year, with an ambition of 15 annually by 2030 and beyond 20 after that. AI chief Mishal Patel offered one specific case study: an active-learning system combining a protein language model, predictive models, and an optimization engine achieved a 500-fold improvement in molecule potency within three design rounds instead of the typical eight, compressing a preclinical discovery campaign to three months. Lange was careful to temper expectations on translating this into clinical success, noting AI gains are "100% in preclinical" so far and that the company still applies "the human angle" before advancing any AI-suggested asset. Investors pressed on whether faster failures were the more likely outcome; Lange's response was measured rather than triumphant, promising to "discuss in a year from now when we have some first human dose data."
Manufacturing: The Oral Cost Moat Gets Quantified
Manufacturing chief Kasper Mejlvang made the most detailed public case yet for Novo's yeast-based fermentation platform as a durable cost advantage over synthetic peptide manufacturing used by competitors, though he declined to quantify the exact margin. CapEx has now peaked — last year was the high-water mark — and is guided down from roughly 20% of sales toward mid-single-digit, industry-level ratios by 2030. The company has invested more than $10 billion in U.S. manufacturing over the past decade, with committed spending pushing that past $12 billion over the next two years, giving Novo a full U.S.-to-U.S. supply chain for the Wegovy pill. CFO Karsten Knudsen pushed back directly on the idea that the oral franchise carries negative gross margin mix risk into 2027: "The Wegovy tablet is reasonably close to group average," he said, dismissing a common investor assumption.
Commercial Execution: Wegovy Pill Outpacing Its Own U.S. Launch Curve in the U.K.
U.S. marketing lead Ed Cinca reported the Wegovy pill is running at roughly 285,000 weekly prescriptions in the U.S., versus about 45,000 for the nearest oral competitor — a gap Cinca translated into roughly 40,000 daily prescriptions versus the competitor's weekly figure. Eighty percent of Wegovy pill patients are GLP-1 naive, and new-to-brand prescription share sits above 80%. International operations chief Emil Larsen offered an even sharper U.K. data point: in the first eight weeks of launch, sell-out volumes tracked the pace of "the best launch in U.S. pharma history," a claim he was careful to caveat by noting the U.S. eventually pulled ahead. Notably, when a competitor entered the U.K. market in week seven, Novo's volumes accelerated rather than declined. Germany, the next major rollout market, has already reached roughly 46,000 in-market patients within two weeks of launch, roughly split between telehealth and traditional channels — with Larsen noting telehealth penetration in Germany has jumped from 7% to 30% of the obesity market in a year.
Ozempic's Rebrand Strategy Is Working as a Naive-Patient Magnet
The relaunch of Rybelsus as "Ozempic pill" — leveraging brand equity rather than a new molecule — is drawing more than 60% of new-to-brand prescriptions from GLP-1-naive patients, a data point management flagged as evidence that "injection barriers are real for either HCPs or patients." In ex-U.S. markets with 2.0-milligram Rybelsus already launched (roughly 10 markets today, 20 by year-end), Novo has flipped from below-market to capturing 7 of 10 new patients choosing Ozempic in Germany and the Netherlands.
Pricing and the LOE Playbook
Management confirmed a baseline planning assumption of roughly 10% annual gradual price decline for GLP-1s, with a sharper step-down expected around the 2031-2032 European semaglutide LOE window — though Doustdar pointed to early-LOE markets like Canada, the Netherlands and Germany as evidence that volume expansion can offset pricing collapse: "The market starts to expand quite a bit... it's not that one loses it to the generics fully." U.S. chief Jamey Millar disclosed that list prices for Rybelsus, Ozempic and Wegovy will drop to $675 beginning January 2027, and confirmed a 10-15% net price degradation trend for Ozempic that is expected to continue, rather than accelerate sharply, into the 2027 Medicaid/IRA pricing transition. Compounding pressure, notably, has faded as a modeling concern — Doustdar noted several large compounders have pivoted to reselling branded product, and Knudsen confirmed "we have no upside baked into our numbers" should U.S. regulators further crack down on compounded semaglutide.
Financial Targets: Mid-Single-Digit Growth, Stable Margins, Falling SG&A
Knudsen framed the deceleration bluntly: after more than doubling revenue and tripling R&D spend over four years of "hyper growth," Novo is now guiding to mid-single-digit compounded revenue growth through 2030, explicitly "on par with our pharma peers" rather than outperforming them — a calibration Simon Baker of Rothschild & Co Redburn pressed on as potentially conservative given uncertain elasticity of obesity demand. Operating margin is targeted to stay broadly stable, with R&D spending continuing to rise as a share of sales (from below 13% four years ago to 17% last year) offset by SG&A compression toward roughly 20% of sales from 23% today. Capital allocation priorities remain: reinvest in the business first, return roughly half of profit via dividends (31 consecutive years of per-share increases), fund bolt-on business development, and deploy excess cash via buybacks — combined dividends and buybacks have returned DKK 270 billion to shareholders over five years. On larger M&A, Doustdar left the door open when pressed directly: "I would not rule it out," though Knudsen reiterated the bolt-on strategy remains the base case for now.
The Restructuring Backdrop
The numbers behind the transformation are stark: Novo cut 9,000 jobs last year and a further 4,000 since, taking headcount down 13,000 from a year ago, alongside unifying R&D under one organization and cutting Lange's direct reports by more than half. Doustdar was unusually candid about the human cost: "These are not easy decisions for us, but they were necessary." The payoff, according to management, shows up in revenue per employee, up nearly 50%, and in R&D throughput — first-human-dose starts already exceeding last year's total by August.